NASH
MCID: NNL002
MIFTS: 53

Nonalcoholic Steatohepatitis (NASH)

Categories: Liver diseases, Rare diseases

Aliases & Classifications for Nonalcoholic Steatohepatitis

MalaCards integrated aliases for Nonalcoholic Steatohepatitis:

Name: Nonalcoholic Steatohepatitis 53 73
Non-Alcoholic Fatty Liver Disease 53
Non-Alcoholic Steatohepatitis 53
Nash 53

Classifications:



External Ids:

UMLS 73 C3241937

Summaries for Nonalcoholic Steatohepatitis

NIH Rare Diseases : 53 Nonalcoholic steatohepatitis, or NASH, is a common, often �??silent�?� liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly. NASH most often occurs in people who are middle aged and overweight or obese. Affected individuals may also have elevated levels of blood lipids (such as cholesterol and triglycerides) and many have diabetes or prediabetes. Treatment is centered around working towards a healthy lifestyle, including weight reduction, dietary modification, increased activity and avoidance of alcohol and unnecessary medications. The underlying cause of NASH remains unclear.

MalaCards based summary : Nonalcoholic Steatohepatitis, also known as non-alcoholic fatty liver disease, is related to fatty liver disease and nonalcoholic fatty liver disease. An important gene associated with Nonalcoholic Steatohepatitis is SQSTM1 (Sequestosome 1), and among its related pathways/superpathways are Common Cytokine Receptor Gamma-Chain Family Signaling Pathways and Selenium Micronutrient Network. The drugs Ezetimibe and Metformin have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Non-alcoholic fatty liver disease (NAFLD) is a condition where excess fat builds up in the liver due to... more...

Related Diseases for Nonalcoholic Steatohepatitis

Diseases related to Nonalcoholic Steatohepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 273)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 32.1 ADIPOQ CYP2E1 INS LEP PNPLA3 SLC17A5
2 nonalcoholic fatty liver disease 32.0 ADIPOQ CYP2E1 INS KRT18 LEP PNPLA3
3 hepatitis c 30.9 GPT KRT18 TNF
4 glucose intolerance 30.7 ADIPOQ INS LEP
5 atherosclerosis susceptibility 30.6 ADIPOQ INS TNF
6 hepatitis 30.6 F2 GPT KRT18 SLC17A5 TNF
7 hemosiderosis 30.6 GPT HFE
8 arteries, anomalies of 30.5 ADIPOQ INS LEP TNF
9 lipid metabolism disorder 30.5 ADIPOQ INS LEP
10 sleep apnea 30.3 ADIPOQ INS LEP TNF
11 morbid obesity 30.3 ADIPOQ INS LEP
12 chronic kidney failure 30.3 ADIPOQ INS LEP
13 cryptogenic cirrhosis 30.2 F2 HFE KRT18
14 prader-willi syndrome 30.2 ADIPOQ INS LEP
15 diabetes mellitus 30.2 ADIPOQ HFE INS LEP TNF
16 gestational diabetes 30.1 ADIPOQ INS LEP
17 hepatitis b 30.1 F2 GPT SLC17A5 TNF
18 hyperglycemia 30.1 ADIPOQ INS LEP
19 fatty liver disease, nonalcoholic 1 30.1 ADIPOQ GPT INS KRT18 LEP SLC17A5
20 acanthosis nigricans 30.1 ADIPOQ INS LEP
21 portal hypertension 30.1 F2 GPT TNF
22 apnea, obstructive sleep 30.0 ADIPOQ INS LEP TNF
23 infantile liver failure syndrome 1 29.9 F2 GPT SLC17A5
24 cholangitis 29.9 F2 GPT TNF
25 hepatitis a 29.9 F2 GPT TNF
26 acute liver failure 29.9 F2 GPT SLC17A5
27 diabetes mellitus, noninsulin-dependent 29.8 ADIPOQ GPT INS LEP SLC17A5 TNF
28 bilirubin metabolic disorder 29.8 F2 GPT SLC17A5
29 alcoholic hepatitis 29.8 CYP2E1 F2 GPT KRT18 SLC17A5 TNF
30 vascular disease 29.8 ADIPOQ F2 INS TNF
31 overnutrition 29.7 ADIPOQ INS LEP TNF
32 pre-eclampsia 29.7 ADIPOQ F2 LEP TNF
33 liver disease 29.5 ADIPOQ CYP2E1 F2 GPT HFE INS
34 alcoholic liver cirrhosis 29.4 CYP2E1 F2 PNPLA3 SLC17A5
35 body mass index quantitative trait locus 11 29.2 ADIPOQ CYP2E1 GPT INS LEP PNPLA3
36 liver cirrhosis 29.2 ADIPOQ CYP2E1 F2 GPT HFE KRT18
37 viral hepatitis 29.1 F2 GPT HFE KRT18 SLC17A5 TNF
38 hepatocellular carcinoma 10.8
39 hepatitis c virus 10.4
40 colorectal cancer 10.3
41 hypertension, essential 10.3
42 heart disease 10.3
43 polycystic ovary syndrome 1 10.3
44 coronary artery anomaly 10.3
45 prostatic hyperplasia, benign 10.2
46 nutritional deficiency disease 10.2
47 periodontitis 10.2
48 paraquat poisoning 10.2 GPT SLC17A5
49 burns 10.2 INS TNF
50 adult dermatomyositis 10.2 GPT TNF

Graphical network of the top 20 diseases related to Nonalcoholic Steatohepatitis:



Diseases related to Nonalcoholic Steatohepatitis

Symptoms & Phenotypes for Nonalcoholic Steatohepatitis

MGI Mouse Phenotypes related to Nonalcoholic Steatohepatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.09 ADIPOQ CYP2E1 F2 HFE INS LEP
2 homeostasis/metabolism MP:0005376 10.07 ADIPOQ CYP2E1 F2 HFE INS LEP
3 growth/size/body region MP:0005378 10.06 ADIPOQ F2 HFE INS KRT18 LEP
4 adipose tissue MP:0005375 9.93 ADIPOQ INS LEP PNPLA3 SQSTM1 TNF
5 liver/biliary system MP:0005370 9.91 ADIPOQ CYP2E1 HFE INS KRT18 LEP
6 mortality/aging MP:0010768 9.85 ADIPOQ CYP2E1 F2 HFE INS KRT18
7 integument MP:0010771 9.8 ADIPOQ F2 INS LEP SQSTM1 TNF
8 nervous system MP:0003631 9.56 ADIPOQ F2 HFE INS LEP SLC17A5
9 skeleton MP:0005390 9.23 ADIPOQ F2 GPT HFE INS LEP

Drugs & Therapeutics for Nonalcoholic Steatohepatitis

Drugs for Nonalcoholic Steatohepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 259)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
2
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
3
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1406-66-2 14986
4
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
5
Peginterferon alfa-2a Approved, Investigational Phase 4,Not Applicable 198153-51-4 5360545
6
Ribavirin Approved Phase 4,Not Applicable 36791-04-5 37542
7
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Not Applicable 122320-73-4 77999
8
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
9
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
10
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
11
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
12
Rifaximin Approved, Investigational Phase 4,Not Applicable 80621-81-4 6436173
13
Empagliflozin Approved Phase 4 864070-44-0
14 Dulaglutide Approved, Investigational Phase 4,Not Applicable 923950-08-7
15
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
16
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
17
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-02-9 14985
18
Methionine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 63-68-3 6137
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
20 Tocotrienol Investigational Phase 4,Phase 3,Phase 2,Not Applicable 6829-55-6
21 Anticholesteremic Agents Phase 4,Phase 2,Phase 1
22 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Hypoglycemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Tocotrienols Phase 4,Phase 3,Phase 2,Not Applicable
27 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Tocopherols Phase 4,Phase 3,Phase 2,Not Applicable
29 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 insulin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Antioxidants Phase 4,Phase 3,Phase 2,Not Applicable
35 Micronutrients Phase 4,Phase 3,Phase 2,Not Applicable
36 Trace Elements Phase 4,Phase 3,Phase 2,Not Applicable
37 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Vitamins Phase 4,Phase 3,Phase 2,Not Applicable
39 Immunologic Factors Phase 4,Phase 2,Not Applicable
40 Antiviral Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 interferons Phase 4,Not Applicable
43 Interferon-alpha Phase 4,Not Applicable
44 Antihypertensive Agents Phase 4,Phase 3,Phase 2
45 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3,Phase 2
46 Angiotensinogen Phase 4,Phase 3,Phase 2
47 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 2
48 Anti-Obesity Agents Phase 4
49 Incretins Phase 4,Phase 2,Phase 3,Not Applicable
50 Glucagon-Like Peptide 1 Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 357)
# Name Status NCT ID Phase Drugs
1 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
2 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
3 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
4 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
5 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
6 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
7 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
8 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
9 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
10 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
11 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4 Ribavirin;Peginterferon alfa-2a;Ribavirin;Peginterferon alfa-2a
12 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Recruiting NCT02964715 Phase 4 Empagliflozin
13 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Enrolling by invitation NCT02210715 Phase 4 Isentress.
14 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis Not yet recruiting NCT03198572 Phase 4 Placebo;Berberine
15 Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) Not yet recruiting NCT03648554 Phase 4 dulaglutide (TRULICITY®) 1.5 mg
16 Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH Terminated NCT01406704 Phase 4 Rosiglitazone;alpha-lipoic acid;Rosiglitazone/alpha-lipoic acid
17 Rifaximin in Fatty Liver Disease Terminated NCT01355575 Phase 4 Rifaximin
18 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4 Femarelle
19 Regression of Fatty Heart by Valsartan Therapy Withdrawn NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
20 Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01623024 Phase 3 Vitamin D
21 The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver Unknown status NCT02530138 Phase 2, Phase 3
22 Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Unknown status NCT00658164 Phase 3
23 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
24 Metformin in Non-Alcoholic Fatty Liver Disease Unknown status NCT00303537 Phase 2, Phase 3 metformin
25 The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT01791959 Phase 2, Phase 3
26 Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis Completed NCT00820651 Phase 3
27 Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH) Completed NCT00681408 Phase 2, Phase 3 Omega 3 Fish Oil supplements;Placebo
28 Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) Completed NCT00063622 Phase 3 Pioglitazone;Matching placebo
29 Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis Completed NCT00509418 Phase 3
30 Anti-Fibrotic Effects of Losartan In Nash Evaluation Study Completed NCT01051219 Phase 3 Losartan
31 Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH Completed NCT00267670 Phase 2, Phase 3 Pentoxifylline;Placebo
32 S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis Completed NCT00108589 Phase 3 S-adenosylmethionine
33 Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Completed NCT01934777 Phase 3 Docosahexaenoic Acid plus Vitamin E plus choline;placebo pearls
34 The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT02030977 Phase 2, Phase 3
35 A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH Completed NCT02279524 Phase 2, Phase 3 Aramchol
36 The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Completed NCT02395900 Phase 2, Phase 3
37 Omega 3 Supplementation in Fatty Liver Completed NCT01992809 Phase 3
38 Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Completed NCT00063635 Phase 3 Metformin;Matching placebo
39 Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group Completed NCT01754714 Phase 3 SAMe 1000 mg;SAMe 1500 mg;SAMe 2000 mg
40 DHA and Vitamin D in Children With Biopsy-proven NAFLD Completed NCT02098317 Phase 3 DHA plus Vitamin D;Placebo
41 Development of a Breath Test for Monitoring Patients With Liver Disease Completed NCT00244569 Phase 3 13C-Methacetin
42 Role of Exenatide in NASH-a Pilot Study Completed NCT00650546 Phase 2, Phase 3 Exenatide
43 Hydroxytyrosol and Vitamin E in Pediatric NASH Completed NCT02842567 Phase 3 Hydroxytyrosol plus Vitamin E;Placebo
44 Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity Completed NCT00553852 Phase 3 Recombinant GH Saizen (Merck-Serono)
45 Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Completed NCT00655018 Phase 2, Phase 3
46 Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) Recruiting NCT02704403 Phase 3 Elafibranor;Placebo
47 Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Recruiting NCT02548351 Phase 3 Obeticholic Acid;Placebo
48 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Recruiting NCT03439254 Phase 3 Obeticholic acid (10 mg);Obeticholic acid (10 mg to 25 mg);Placebo
49 Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults Recruiting NCT02654665 Phase 3 Liraglutide
50 AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH Recruiting NCT03028740 Phase 3 Cenicriviroc;Placebo

Search NIH Clinical Center for Nonalcoholic Steatohepatitis

Genetic Tests for Nonalcoholic Steatohepatitis

Anatomical Context for Nonalcoholic Steatohepatitis

MalaCards organs/tissues related to Nonalcoholic Steatohepatitis:

41
Liver, Testes, Heart, Endothelial, Ovary, Kidney, Bone

Publications for Nonalcoholic Steatohepatitis

Articles related to Nonalcoholic Steatohepatitis:

(show top 50) (show all 2312)
# Title Authors Year
1
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. ( 30430605 )
2019
2
Vitamin E alleviates non-alcoholic fatty liver disease in phosphatidylethanolamine N-methyltransferase deficient mice. ( 30300671 )
2019
3
Olive oil lessened fatty liver severity independent of cardiometabolic correction in patients with non-alcoholic fatty liver disease: A randomized clinical trial. ( 30170304 )
2019
4
Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease. ( 30016770 )
2019
5
Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis? ( 30454829 )
2019
6
Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. ( 29381754 )
2018
7
Macrophages in Nonalcoholic Steatohepatitis: Friend or Foe? ( 29930864 )
2018
8
Synbiotics Bifidobacterium infantis and milk oligosaccharides are effective in reversing cancer-prone nonalcoholic steatohepatitis using western diet-fed FXR knockout mouse models. ( 29800811 )
2018
9
Risk of Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis. ( 29942224 )
2018
10
Metabolic Syndrome is Associated with Health-Related Quality of Life in Suspected Patients with Nonalcoholic Steatohepatitis. ( 29402822 )
2018
11
Enhanced expression and distinctive characterization of a long-acting FGF21 and its potential to alleviate nonalcoholic steatohepatitis. ( 29870802 )
2018
12
Rates and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. ( 29913275 )
2018
13
Characterization of a murine nonalcoholic steatohepatitis model induced by high fat high calorie diet plus fructose and glucose in drinking water. ( 29959418 )
2018
14
Haptoglobin Genotype and VitaminA E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. ( 29411270 )
2018
15
The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis. ( 29291351 )
2018
16
Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis. ( 29930468 )
2018
17
Nonalcoholic steatohepatitis: the new frontier for liver transplantation. ( 29356708 )
2018
18
Hyperlipidemia and Nonalcoholic Steatohepatitis Predispose to Hepatocellular Carcinoma Development Without Cirrhosis. ( 29912756 )
2018
19
Physical deconditioning is the common denominator in both obese and overweight subjects with nonalcoholic steatohepatitis. ( 29797529 )
2018
20
Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis. ( 29802399 )
2018
21
Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. ( 29761169 )
2018
22
Risk factors and clinical course for liver steatosis or nonalcoholic steatohepatitis after living donor liver transplantation. ( 29894414 )
2018
23
Organic Solute Transporter OSTI+/A9 is Over-Expressed in Nonalcoholic Steatohepatitis and Modulated by Drugs Associated with Liver Injury. ( 29420067 )
2018
24
Dual regulation of HMGB1 by combined JNK1/2-ATF2 axis with miR-200 family in nonalcoholic steatohepatitis in mice. ( 29298863 )
2018
25
A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol diet. ( 29311502 )
2018
26
Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis. ( 29555473 )
2018
27
Misregulation of membrane trafficking processes in human nonalcoholic steatohepatitis. ( 29341352 )
2018
28
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. ( 29406435 )
2018
29
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. ( 29375204 )
2018
30
Dietary Iron Supplementation Alters Hepatic Inflammation in a Rat Model of Nonalcoholic Steatohepatitis. ( 29401710 )
2018
31
Relationship between intestinal flora and inflammatory factors in patients with nonalcoholic steatohepatitis. ( 29399077 )
2018
32
A comprehensive bioinformatics analysis on multiple Gene Expression Omnibus datasets of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. ( 29769552 )
2018
33
Imaging prediction of nonalcoholic steatohepatitis using computed tomography texture analysis. ( 29404772 )
2018
34
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. ( 29367468 )
2018
35
Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. ( 29299759 )
2018
36
The accuracy of noninvasive scoring systems for diagnosing nonalcoholic steatohepatitis-related fibrosis: multi-center validation study. ( 29974624 )
2018
37
Inflammasome activation in Kupffer cells confers a protective response in nonalcoholic steatohepatitis through pigment epithelium-derived factor expression. ( 29897812 )
2018
38
IL6R Gene Polymorphic Variant rs2228145(C >A) as a Marker of Genetic Liability to Nonalcoholic Steatohepatitis in the Russian Population of Karelia. ( 29797122 )
2018
39
Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis. ( 29912761 )
2018
40
Mouse Models Of Nonalcoholic Steatohepatitis: A Reflection On Recent Literature. ( 29424123 )
2018
41
Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage. ( 29881817 )
2018
42
Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven Nonalcoholic Steatohepatitis. ( 30536602 )
2018
43
Non-alcoholic fatty liver disease in patients with autoimmune hepatitis. ( 30483564 )
2018
44
Non-alcoholic fatty liver disease and colorectal cancer survival. ( 30443695 )
2018
45
Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. ( 29627620 )
2018
46
Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016. ( 30075518 )
2018
47
Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. ( 29399276 )
2018
48
Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. ( 30551263 )
2018
49
Non-alcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes mellitus. ( 30470912 )
2018
50
Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. ( 30473540 )
2018

Variations for Nonalcoholic Steatohepatitis

Expression for Nonalcoholic Steatohepatitis

Search GEO for disease gene expression data for Nonalcoholic Steatohepatitis.

Pathways for Nonalcoholic Steatohepatitis

GO Terms for Nonalcoholic Steatohepatitis

Cellular components related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 ADIPOQ F2 GPT HFE INS LEP

Biological processes related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.78 INS LEP TNF
2 regulation of signaling receptor activity GO:0010469 9.72 ADIPOQ F2 INS LEP TNF
3 response to ethanol GO:0045471 9.69 ADIPOQ CYP2E1 LEP
4 glucose homeostasis GO:0042593 9.67 ADIPOQ INS LEP
5 positive regulation of glucose import GO:0046326 9.65 ADIPOQ INS
6 response to bacterium GO:0009617 9.65 ADIPOQ CYP2E1 SLC17A5
7 positive regulation of reactive oxygen species metabolic process GO:2000379 9.64 F2 LEP
8 positive regulation of cytokine production GO:0001819 9.64 LEP TNF
9 positive regulation of cytokine secretion GO:0050715 9.63 INS TNF
10 positive regulation of interleukin-8 production GO:0032757 9.63 ADIPOQ TNF
11 positive regulation of JAK-STAT cascade GO:0046427 9.62 F2 LEP
12 negative regulation of proteolysis GO:0045861 9.62 F2 INS
13 positive regulation of protein localization to nucleus GO:1900182 9.61 F2 INS
14 leukocyte tethering or rolling GO:0050901 9.6 LEP TNF
15 positive regulation of long-term synaptic potentiation GO:1900273 9.59 INS SQSTM1
16 negative regulation of lipid catabolic process GO:0050995 9.58 INS TNF
17 positive regulation of cellular protein metabolic process GO:0032270 9.58 ADIPOQ INS
18 positive regulation of insulin receptor signaling pathway GO:0046628 9.57 INS LEP
19 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.56 SQSTM1 TNF
20 positive regulation of protein phosphorylation GO:0001934 9.56 ADIPOQ F2 SQSTM1 TNF
21 negative regulation of gluconeogenesis GO:0045721 9.55 ADIPOQ INS
22 negative regulation of glucose import GO:0046325 9.54 LEP TNF
23 negative regulation of growth of symbiont in host GO:0044130 9.52 SQSTM1 TNF
24 regulation of protein secretion GO:0050708 9.46 INS TNF
25 negative regulation of lipid storage GO:0010888 9.43 LEP TNF
26 positive regulation of peptide hormone secretion GO:0090277 9.4 HFE INS
27 negative regulation of receptor binding GO:1900121 9.37 ADIPOQ HFE
28 acute-phase response GO:0006953 9.33 F2 HFE INS
29 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.26 F2 INS LEP TNF
30 glucose metabolic process GO:0006006 8.92 ADIPOQ INS LEP TNF

Molecular functions related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.26 ADIPOQ F2 HFE LEP
2 hormone activity GO:0005179 8.8 ADIPOQ INS LEP

Sources for Nonalcoholic Steatohepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....